NCHR Testimony at FDA Advisory Committee on Anti-Infective Drugs

December 4, 2014. Antibiotic resistance and the inability to treat common infections is an increasingly urgent public health crisis which affects everyone, especially some of the most vulnerable in our society. Finding treatment options for unmet populations is urgently important but ineffective antibiotics lead to an increase in antibiotic resistance.

Read More »

NCHR Testimony at EPA Scientific Advisory Panel

December 3, 2014. Research has implicated endocrine-disrupting chemicals in cancer, infertility, and other health problems. We must be able to quickly identify such agents in order to prevent them from entering our food and environment, and from affecting our health for generations to come.

Read More »

NCHR Testimony at FDA Risk Communication Advisory Committee on Fish Consumption

November 3, 2014. NCHR states that most consumers don’t want to have a long list of exactly what kind of fish to eat and what to avoid. If pregnant and breastfeeding women have avoided fish for themselves and for their young children, it’s because the messages they were getting were confusing. Come up with phrases that are easy to remember and and messages that are straightforward.

Read More »

NCHR Comments on FDA Safety and Innovation Act Action Plan

October 21, 2014. NCHR strongly supports inclusion of separate analysis of safety and effectiveness for demographic subgroups in clinical trials for drugs and devices. It is essential that methodologically sound data about how drugs and devices work in these groups be conducted and made publicly available.

Read More »